Great Tree Pharmacy Co., Ltd. AI Stock Analysis
Great Tree Pharmacy Co., Ltd. (6469) AI Stock Analysis
Great Tree Pharmacy Co., Ltd.
(TPEx:6469)
Great Tree Pharmacy scores in the middle of the range. Financial fundamentals are the dominant driver: strong revenue growth, improving gross margins and consistently positive free cash flow are genuine strengths, but shrinking operating and net margins, three straight years of lower net income, and debt at roughly 1.8x equity with weakening cash coverage are material risks. Technicals are the biggest drag — the shares sit well below all major moving averages with negative MACD, and while deeply oversold readings suggest the move is extended, there is no confirmation of a turn. Valuation provides the main offset, with a moderate 17.1x P/E and an attractive 5.46% dividend yield, although payout sustainability warrants monitoring given the earnings trend. Low beta (0.12) means the stock's weakness is company-specific rather than market-driven.
Great Tree Pharmacy Co., Ltd. (6469) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 9.11B
- Dividend Yield
- 5.46%
- Average Volume (3M)
- 401.78K
- Price to Earnings (P/E)
- 16.6
- Beta (1Y)
- 0.12
- Revenue Growth
- 4.00%
- EPS Growth
- -25.06%
- Country
- TW
- Employees
- 446
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Great Tree Pharmacy Co., Ltd. Business Overview & Revenue Model
Company Description
Great Tree Pharmacy Co., Ltd. is a Taiwanese enterprise that operates an extensive chain of pharmacies throughout the island nation. These retail outlets offer a broad selection of goods, including prescription and over-the-counter medications, nutri...
Great Tree Pharmacy Co., Ltd. Financial Statement Overview
Summary
Mixed quality. Revenue has compounded at roughly 17% annually since 2020 (NT$8.6bn to NT$18.9bn) with gross margin improving to 28.7%, and cash generation is solid — operating cash flow of NT$1.17bn and a sixth straight year of positive free cash flow (NT$787m). Offsetting this, operating margin has fallen from 6.4% to 4.4%, net income has declined for three consecutive years, and leverage is elevated at ~1.8x debt-to-equity with equity funding only ~28% of assets. Return on equity remains respectable at 15.3% but has dropped sharply from 26.9% in 2022, indicating the store-expansion strategy is delivering diminishing returns.
Income Statement
64PositiveBalance Sheet
48NeutralCash Flow
69Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.02B | 18.90B | 17.27B | 16.14B | 14.56B | 11.28B |
| Gross Profit | 5.43B | 5.42B | 4.84B | 4.49B | 4.01B | 2.94B |
| EBITDA | 1.52B | 1.71B | 1.71B | 1.60B | 1.54B | 1.04B |
| Net Income | 515.77M | 600.42M | 680.77M | 666.05M | 700.07M | 407.42M |
Balance Sheet | ||||||
| Total Assets | 14.02B | 13.76B | 12.13B | 10.77B | 10.12B | 7.39B |
| Cash, Cash Equivalents and Short-Term Investments | 2.53B | 2.54B | 2.23B | 2.16B | 2.48B | 1.33B |
| Total Debt | 6.44B | 7.07B | 6.00B | 5.14B | 5.13B | 3.83B |
| Total Liabilities | 10.28B | 9.76B | 8.48B | 7.42B | 7.49B | 5.44B |
| Stockholders Equity | 3.67B | 3.92B | 3.60B | 3.28B | 2.60B | 1.93B |
Cash Flow | ||||||
| Free Cash Flow | 623.39M | 787.01M | 779.64M | 564.03M | 910.93M | 823.18M |
| Operating Cash Flow | 965.15M | 1.17B | 1.14B | 890.33M | 1.23B | 1.08B |
| Investing Cash Flow | -684.52M | -880.71M | -881.37M | -416.53M | -465.58M | -268.43M |
| Financing Cash Flow | -597.02M | -409.63M | -499.08M | -795.84M | 389.10M | -336.57M |
Great Tree Pharmacy Co., Ltd. Peers Comparison
Overall Rating
TW:120370Outperform
TW:679068.2Neutral
TW:653467Neutral
TW:843662Neutral
TW:646956Neutral
TW:170243Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | TWD 10.47B | 21.08 | ― | 2.27% | -13.42% | 12.83% | |
| 68Neutral | TWD 9.84B | 11.96 | ― | 7.19% | -3.83% | 17.72% | |
| 67Neutral | TWD 8.35B | 15.17 | ― | 6.17% | 6.31% | 31.07% | |
| 62Neutral | TWD 10.68B | 9.60 | ― | 6.52% | -3.82% | 2.23% | |
| 56Neutral | TWD 9.20B | 16.65 | ― | 5.46% | 4.00% | -25.06% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 43Neutral | TWD 7.65B | 46.74 | ― | 5.19% | -0.31% | -90.22% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6469 | Great Tree Pharmacy Co., Ltd. | 57.80 | -36.31 | -38.59% | |
| TW:1203 | Ve Wong Corporation | 44.05 | 5.25 | 13.52% | |
| TW:1702 | Namchow Holdings Co., Ltd. | 30.85 | -6.87 | -18.22% | |
| TW:6534 | CH Biotech R&D Co., Ltd. | 86.00 | -4.67 | -5.15% | |
| TW:6790 | Yuen Foong Yu Consumer Products Co., Ltd. | 36.85 | 1.42 | 4.02% | |
| TW:8436 | TCI Co., Ltd. | 92.20 | -24.45 | -20.96% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
